Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma
暂无分享,去创建一个
[1] K. Rieger,et al. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. , 2019, The Journal of investigative dermatology.
[2] M. Chren,et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib , 2017, Journal of the American Academy of Dermatology.
[3] A. Henry,et al. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. , 2016, JAMA dermatology.
[4] Jean Y. Tang,et al. Squamous Change in Basal-Cell Carcinoma with Drug Resistance. , 2015, The New England journal of medicine.
[5] B. Dréno,et al. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] L. Thomas,et al. Fast-Growing Cutaneous Squamous Cell Carcinoma in a Patient Treated with Vismodegib , 2015, Dermatology.
[7] A. Chang,et al. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. , 2014, JAMA dermatology.
[8] J. Utikal,et al. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma , 2014, The British journal of dermatology.
[9] V. Sondak,et al. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. , 2013, Journal of the American Academy of Dermatology.
[10] J. Kolesar,et al. Vismodegib for the treatment of basal cell skin cancer. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.